Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine

Therapeutic Drug Monitoring

Volumn 18, Issue 2, 1996, Pages 164-167

  Otani, K ^a   Ishida, M ^a   Kaneko, S ^a   Mihara, K ^a   Ohkubo, T ^a   Osanai, T ^b   Sugawara, K ^a  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Goshogawara City Hospital   (Japan)

Author keywords

Carbamazepine; m Chlorophenylpiperazine; Metabolism; Plasma concentration; Trazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CARBAMAZEPINE; CYTOCHROME P450; DRUG METABOLITE; TRAZODONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARBAMAZEPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SEROTONIN AGONISTS; TRAZODONE;

EID: 0029964624     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199604000-00010     Document Type: Article

References (23)

1. Post RM, Ketter TA, Pazzaglia PJ, Denicoff K, Marangell L, George MS. Anticonvulsants in refractory mood disorders. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD, eds. Refractory depression: current strategies and future directions. Chichester: John Wiley, 1994:97-114.
2. Brown CS, Wells BG, Cold JA, Froemming JH, Self TH, Jabbour JT. Possible influence of carbamazepine on plasma concentrations in children with attention deficit hyperactive disorder. J Clin Psychopharmacol 1990;10:359-62.
3. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991;11: 313-8.
4. Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993;15: 258-60.
5. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
6. Kutcher SP, Reid K, Dubbin JD, Shulman KI. Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives. Br J Psychiatry 1986;148:676-9.
7. Nordin C, Bertilsson L, Siwers B. Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. Clin Pharmacol Ther 1987; 42:10-9.
8. Nelson JC, Mazure C, Jatlow PI. Antidepressant activity of 2-hydroxydesipramine. Clin Pharmacol Ther 1988;44:283-8.
9. Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y. Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin? Hum Psychopharmacol 1991;6:243-8.
10. Baldessarini RJ, Teicher MH, Cassidy JW, Stein MH. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988;8:381-2.
11. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-66.
12. Ohkubo T, Osanai T, Sugawara K, et al. High-performance liquid chromatographic determination of trazodone and 1-m-chlorophenylpiperazine with ultraviolet and electrochemical detector. J Pharm Pharmacol 1995;47:340-4.
13. Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady-state plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995;10:143-6.
14. Jauch R, Kopitar Z, Prox A, Zimmer A. Pharmakokinetik und Stoffwechsel von Trazodone beim Menschen. Arzneimittelforschung 1976;26:2084-9.
15. Mayol RF, Cole CA, Colson KE, Kerns EH. Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat. Drug Metab Dispos 1994;22: 171-4.
16. Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995;17:333-5.
17. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyl transferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994; 4:209-18.
18. Riblet LA, Taylor DP. Pharmacology and neurochemistry of trazodone. J Clin Psychopharmacol 1981;1(suppl):17S-22S.
19. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 1986; 11:177-98.
20. Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989;36: 401-6.
21. Yue Q-Y, Tomson T, Sawe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994;4:193-8.
22. Mizuno K, Okada M, Kaneko S, et al. Effects of zonisamide, carbamazepine and valproate on monoamine metabolism in rat striatum and hippocampus. Jpn J Psychiatry Neurol 1994;48:406-8.
23. Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol (in press).